Osteoprotegerin administration reduces femural bone loss in ovariectomized mice via impairment of osteoclast structure and function

Journal of Electron Microscopy

Volumn 51, Issue 5, 2002, Pages 315-325

  Shimizu Ishiura, Miho ^a   Kawana, Fumi ^a   Sasaki, Takahisa ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Bone resorption; Osteoclast; Osteoporosis; Osteoprotegerin; Ovariectomy; Vacuolar type H+ ATPase

Indexed keywords

CELL RECEPTOR; GLYCOPROTEIN; OSTEOPROTEGERIN; PROTEIN SYNTHESIS INHIBITOR; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; TNFRSF11B PROTEIN, MOUSE; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL; ARTICLE; DISEASE MODEL; DRUG EFFECT; ELECTRON MICROSCOPY; ENZYMOLOGY; FEMUR; METABOLISM; MOUSE; OSTEOCLAST; OSTEOPOROSIS; OVARIECTOMY; PATHOLOGY; PATHOPHYSIOLOGY; ULTRASTRUCTURE;

ANIMALS; DISEASE MODELS, ANIMAL; FEMUR; GLYCOPROTEINS; MICE; MICROSCOPY, ELECTRON; OSTEOCLASTS; OSTEOPOROSIS; OSTEOPROTEGERIN; OVARIECTOMY; PROTEIN SYNTHESIS INHIBITORS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; VACUOLAR PROTON-TRANSLOCATING ATPASES;

ANIMALIA;

BACKSCATTERING; CELL DEATH; MAMMALS; OSTEOBLASTS;

BASE LINE; BONE LOSS; BONE RESORPTION; H +-ATPASE; OSTEOCLAST; OSTEOPOROSIS; OSTEOPROTEGERIN; OVARIECTOMY; TRABECULAR BONES; VACUOLAR-TYPE H+-ATPASE;

BONE;

EID: 0036412125     PISSN: 00220744     EISSN: None     Source Type: Journal    
DOI: 10.1093/jmicro/51.5.315     Document Type: Article

References (37)

1. Simonet W S, Lacey D L, Dunstan C R, Kelley M, Chang M S, Luthy R, Nguyen H Q, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan H L, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes T M, Hill D, Pattison W, Campbell P, Sander S, van G, Tarpley J, Derby P, Lee R, Amgen EST Program, and Boyle W J (1997) Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89: 309-319.
2. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, and Higashio K (1997) Isolation of a novel cytokine from human fibro-blasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 234: 137-142.
3. Yasuda H, Shima N, Nakagawa N, Mochizuki S, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Karmo T, Murakami A, Tsuda E, Morinaga T, and Higashio K (1998) Identity of osteoclastogenesis inhibitory factor (OC1F) and osteoprotegerin (OPG): A mechanism by which OPG/OC1F inhibits osteoclastogenesis in vitro. Endocrinology 139: 1329-1337.
4. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda A, Morinaga T, Higashio K, Udagawa N, Takahashi N, and Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95: 3597-3602.
5. Akatsu T, Murakami T, Nishikawa M, Ono K, Shinomiya N, Tsuda E, Mochizuki S, Yamaguchi K, Kinosaki M, Higashio K, Yamamoto M, Motoyoshi K, and Nagata N (1998) Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. Biochem. Biophys. Res. Commun. 250: 229234.
6. Matsuzaki K, Udagawa N, Takahashi N, Yamaguchi K, Yasuda H, Shima N, Moronaga T, Toyama Y, Yabe Y, Higashio K, and Suda T (1998) Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem. Biophys. Res. Commun. 246: 199-204.
7. Atkins G J, Bouralexis S, Haynes D R, Graves S E, Geary S M, Evdokiou A, Zannettino A C W, Hay S, and Findlay D M (2001) Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone 28: 370-377.
8. Fuller K, Wong B, Fox S, Choi Y, and Chambers T J (1998) TRANCE is necessary and sufficient for osteoclast-mediated activation of bone resorption in osteoclasts. J Exp. Med. 188: 997-1001.
9. Lacey D L, Timms E, Tan H L, Kelley M J, Dunstan C R, Burgess T, Elliott R, Colombero A, Elliott G, Hsu H, Sullivan J, Hakins N, Davy E, Capparelli C, Eli A, Qian Y X, Kaufman S, Sarosi I, Shalhoub V, Senalddi G, Guo J, Delaney J, and Boyle W J (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176.
10. 2, or parathyroid hormone in the microenvironment of bone. Biochem. Biophys. Res. Commun. 246: 337-341.
11. Hsu H, Lacey D L, Dunstan C R, Solovyev I, Colombero A, Timms E, Tan H L, Elliott G, Kelley M J, Sarosi I, Wang L, Xia X Z, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass M B, and Boyle W J (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96: 3540-3545.
12. Jimi E, Akiyama S, Tsurukai T, Okahashi N, Kobayashi K, Udagawa N, Nishimura T, Takahashi N, and Suda T (1999) Osteoclast differentiation factor act as a multifunctional regulator in murine osteoclast differentiation and function. J. Immunol. 163: 434-442.
13. Takami M, Woo J T, and Nagai K (1999) Osteoblastic cells induce fusion and activation of osteoclasts through a mechanism independent of macrophage-colony-stimulating factor production. Cell Tissue Res. 298: 327-334.
14. Udagawa N, Takahashi N, Jimi E, Matsuzaki K, Tsurukai T, Itoh K, Nakagawa N, Yasuda H, Goto M, Tsuda E, Higashio K, Gillespie M T, Martin T J, and Suda T (1999) Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor. Bone 25: 517-523.
15. Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie M T, Martin T J, Higashio K, and Suda T (2000) Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141: 3478-3484.
16. Helfrich M H, Aronson D C, Everts V, Mieremet J P, Gerritsen E J A Eckhardt P G, Groot C G, and Scherft J P (1991) Morphologic features of bone in human osteoporosis. Bone 12: 411-419.
17. Kalu D N, Salerno E, Liu C C, Ferarro F, Arjmandi B N, and Salih M A (1993) Ovariectomy-induced bone loss and the hematopoietic system. Bone Miner. 23: 145-161.
18. Miller S C and Wronski T J (1993) Long-term osteopenic changes in cancellous bone structure in ovariectomized rats. Anat. Rec. 236: 433-441.
19. Hietala T L (1993) The effect of ovariectomy on periosteal bone formation and bone resorption in adult rats. Bone Miner. 20: 57-65.
20. Danielsen C C, Mosekilde L, and Svenstrup B (1993) Cortical bone mass, composition, and mechanical properties in female rats in relation to age, long-term ovariectomy, and estrogen substitution. Calcif. Tissue Int. 52: 26-33.
21. Mosekilde L, Danielsen C C. and Knudsen U B (1993) The effect of aging and ovariectomy on the vertebral bone mass and biomechanical properties of mature rats. Bone 14: 1-6.
22. Shen V, Dempster D W, Birchman R, Xu R, and Lindsay R (1993) Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol. J. Clin. Invest. 91: 2479-2487.
23. Turner R T, Evans G L, and Wakley G K (1993) Mechanism of action of estrogen on cancellous bone balance in tibiae of ovariectomized growing rats: Inhibition of indices of formation and resorption. J. Bone Miner. Res. 8: 359-366.
24. Barlet J P, Coxam V, Davicco M J, and Gaumet M N (1994) Animal models of post-menopausal osteoporosis. Reproduct. Nutr. Develop. 34: 221-236.
25. Bucay N, Sarosi I, Dunstan C R, Morony S, Tarpley J, Capparelli C, Scully S, Tan H L, Xu W, Lacey D L, Boyle W J, and Simonet W S (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Develop. 12: 1260-1268.
26. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yauo K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, and Ozawa H (1998) Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. 247: 610-615.
27. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, and Yamada Y (1999) Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J. Bone Miner. Res. 14: 518-527.
28. Bateman T A, Dunstan C R, Ferguson V L, Lacey D L, Ayers R A, and Simske S J (2000) Osteoprotegerin mitigates tail suspension-induced osteopenia. Bone 26: 443-449.
29. +-ATPase and its subunit structures. J. Biol. Chem. 31: 18445-18450.
30. O'Brien E A, Williams J H H, and Marshall M J (2001) Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. Bone 28: 208-214.
31. +-ATPase and cathepsin K in osteoclasts during experimental movement of rat molars. Anat. Rec 260: 72-80.
32. Vaes G (1988) Cellular biology and biochemical mechanism of bone resorption. A review of recent developments on the formation, activation, and mode of action of osteoclasts. Clin. Orthop. Rel. Res. 231: 239-271.
33. +-ATPase type in the ruffled borders of osteoclasts. J. Cell Biol. 111: 1305-1311.
34. 3 have ruffled borders and resorb dentine Anat. Rec. 224: 279-291.
35. +-ATPase in osteoclasts and its role in resorption. Cell Tissue Res. 278: 265-271.
36. Sasaki T (1996) Recent advances in the ultrastructural assessment of osteoclastic resorptive functions. Microsc. Res. Techn. 33: 182-191.
37. Shiotani A, Takami M, Itoh K, Shibasaki Y, and Sasaki T (2002) Regulation of osteoclast differentiation and function by receptor activator of NFκB ligand and osteoprotegerin. Anat. Rec. (in press).